Comparison of efficacy between irinotecan and paclitaxel monotherapy as second- or third-line chemotherapy after S-1 containing regimen for advanced or recurrent gastric cancer.

e14722 Background: S-1 is effective and clinically important agent in the initial chemotherapy against advanced or recurrent gastric cancer (ARGC) in Asia. Although several prospective studies on the second-line chemotherapy for ARGC are currently in progress in Japan, the sufficient investigation on the proposition has not been made. We assessed here the clinical efficacy of irinotecan (CPT-11) and paclitaxel (PTX) as the second or thirdline chemotherapeutic agents following the S-1 based treatment, as those has been frequently used in practice. Methods: We conducted the retrospective review of the data of 30 patients with unresectable ARGC who received CPT-11 or PTX monotherapy after administration of S-1 as prior treatment. Each 15 patients were given chemotherapy including CPT-11 and PTX monotherapy treatments, after S-1 containing regimens, as second or third line treatments. The objective response, adverse events, progression-free survival (PFS), and overall survival (OS) were compared between CPT-1...